The mind boggling aspect is that the blockbuster drug for a single indication will have sales in the billions and add market cap in the tens of billions.

My wife believes I am insane (likely true for other reasons) when I discuss back of the envelope valuation projections for leronlimab and Cytodyn.

It appears that leronlimab causes dystonia/occulogyric crisis, at least in my wife.